Stroke-prevenció stroke után pitvarfibrillacióban - eseten alapuló áttekintés.

dc.contributor.author	Kovács, Tibor
dc.date.accessioned	2015-02-04T11:40:56Z
dc.date.available	2015-02-04T11:40:56Z
dc.date.issued	2014
dc.identifier.citation	pagination=1655-1660; journalVolume=155; journalIssueNumber=42; journalTitle=ORVOSI HETILAP;
dc.identifier.uri	http://repo.lib.semmelweis.hu//handle/123456789/1258
dc.identifier.uri	doi:10.1556/OH.2014.30021
dc.description.abstract	Non-valvular atrial fibrillation is one of the most important risk factor for embolic cerebral infarcts. Besides vitamin K antagonists, recently developed novel oral anticoagulants are gaining an increasing role in its treatment. Dabigatran, rivaroxaban and apixaban are novel oral anticoagulants available in the routine clinical practice. This review summarizes their use and the corresponding guidelines in the secondary prevention of ischemic stroke, by answering questions raised in relation of a hypothetical case report.
dc.relation.ispartof	urn:issn:0030-6002
dc.title	Stroke-prevenció stroke után pitvarfibrillacióban - eseten alapuló áttekintés.
dc.type	Journal Article
dc.date.updated	2015-01-27T11:45:54Z
dc.language.rfc3066	hu
dc.identifier.mtmt	2794840
dc.identifier.pubmed	25305723
dc.contributor.department	SE/AOK/K/Neurológiai Klinika
dc.contributor.institution	Semmelweis Egyetem